2,040
Participants
Start Date
November 1, 2019
Primary Completion Date
November 1, 2023
Study Completion Date
November 1, 2026
Dolutegravir / Lamivudine Pill
HIVRNA suppressed patients without documented M184V mutation in HIV RT and who are hepatitis B immune or have no risk factors for acquiring hepatitis B
Rijnstate Hospital, Arnhem
Catharina Ziekenhuis, Eindhoven
Medisch Spectrum Twente, Enschede
Admiraal de Ruyter Ziekenhuis, Goes
Spaarne Gasthuis, Haarlem
Maasstad Hospital, Rotterdam
Elisabeth Tweesteden Hospital, Tilburg
Erasmus MC, Rotterdam
MC Haaglanden, Rotterdam
Lead Sponsor
Collaborators (1)
Maasstad Hospital
OTHER
Haaglanden Medical Centre
OTHER
Catharina Ziekenhuis Eindhoven
OTHER
Elisabeth-TweeSteden Ziekenhuis
OTHER
Rijnstate Hospital
OTHER
Admiraal de Ruyter Hospital
OTHER
Spaarne Gasthuis
OTHER
Medisch Spectrum Twente
OTHER
Erasmus Medical Center
OTHER